Chronic Use of Proton Pump Inhibitors and the Quantity of G, D, and Ecl Cells in the Stomach

Abstract

Background: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells. Aim: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection. Methods: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands. Results: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls. Conclusion: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.

Efeitos adversos do uso contínuo e irracional dos Inibidores de Bomba de Prótons em idosos

“…Estudo realizado por Lukaszuk ( 2017 OLIVEIRA, 2016; ORTIZ-GUERRERO et al, 2018). Essa classe de fármacos exerce grande supressão do ácido gástrico, independentemente de fatores externos estimuladores, e em doses habituais observa-se redução de 80-95% na produção diária de ácido (CAMILO et al, 2020). Como dito anteriormente, os IBP´s é uma classe de fármacos vastamente utilizada pelos idosos, muitas vezes usada sem a devida orientação e sem o uso de prescrição para o tratamento de sintomas dispépticos ou para prevenção dos mesmos (BARBOSA et al, 2021).…”